An overview of liquid chromatographic methods for analyzing new generation anti-epileptic drugs

References

• Falco-Walter, J. J.; Scheffer, I. E.; Fisher, R. S. The New Definition and Classification of Seizures and Epilepsy. Epilepsy Res. 2018, 139, 73–79. DOI: 10.1016/j.eplepsyres.2017.11.015.
   PubMed Web of Science ®Google Scholar
• Thijs, R. D.; Surges, R.; O’Brien, T. J.; Sander, J. W. Epilepsy in Adults. Lancet 2019, 393, 689–701. DOI: 10.1016/S0140-6736(18)32596-0.
   PubMed Web of Science ®Google Scholar
• Lattanzi, S.; Trinka, E.; Zaccara, G.; Striano, P.; Russo, E.; Del Giovane, C.; Silvestrini, M.; Brigo, F. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-Analysis. Drugs 2022, 82, 199–218. DOI: 10.1007/s40265-021-01661-4.
   PubMed Web of Science ®Google Scholar
• Devinsky, O.; Vezzani, A.; O’Brien, T. J.; Jette, N.; Scheffer, I. E.; De Curtis, M.; Perucca, P. Epilepsy. Nat. Rev. Dis. Prim 2018, 4, 18024. DOI: 10.1038/nrdp.2018.24.
   PubMed Web of Science ®Google Scholar
• Perucca, E. Antiepileptic Drugs: Evolution of Our Knowledge and Changes in Drug Trials. Epileptic Disord. 2019, 21, 319–329. DOI: 10.1684/epd.2019.1083.
   PubMed Web of Science ®Google Scholar
• Patsalos, P. N.; Spencer, E. P.; Berry, D. J. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther. Drug Monit. 2018, 40, 526–548. DOI: 10.1097/FTD.0000000000000546.
   PubMed Web of Science ®Google Scholar
• Wesche, D.; MillerSunny, R.; Nancy, C.; Burger, J. A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin. Clin. Pharm. 2012, 49, 661–669.
   Google Scholar
• Cross, A. L.; Viswanath, O.; Sherman, A. L. 2022. Pregabalin. In StatPearls. Treasure Island (FL): StatPearls Publishing.
   Google Scholar
• https://Pubchem.Ncbi.Nlm.Nih.Gov/Compound/219078.
   Google Scholar
• Carona, A.; Bicker, J.; Silva, R.; Fonseca, C.; Falcão, A.; Fortuna, A. Pharmacology of Lacosamide: From Its Molecular Mechanisms and Pharmacokinetics to Future Therapeutic Applications. Life Sci. 2021, 275, 119342. DOI: 10.1016/j.lfs.2021.119342.
   PubMed Web of Science ®Google Scholar
• Patsalos, P. N.; Zugman, M.; Lake, C.; James, A.; Ratnaraj, N.; Sander, J. W. Serum Protein Binding of 25 Antiepileptic Drugs in a Routine Clinical Setting: A Comparison of Free Non–Protein-Bound Concentrations. Epilepsia 2017, 58, 1234–1243. DOI: 10.1111/epi.13802.
   PubMed Web of Science ®Google Scholar
• https://Go.Drugbank.Com/Drugs/DB06201 (accessed March, 2022).
   Google Scholar
• Patsalos, P. N. The Clinical Pharmacology Profile of the New Antiepileptic Drug Perampanel: A Novel Noncompetitive AMPA Receptor Antagonist. Epilepsia 2015, 56, 12–27. DOI: 10.1111/epi.12865.
   PubMed Web of Science ®Google Scholar
• Bialer, M.; Soares-Da-Silva, P. Pharmacokinetics and Drug Interactions of Eslicarbazepine Acetate. Epilepsia 2012, 53, 935–946. DOI: 10.1111/j.1528-1167.2012.03519.x.
   PubMed Web of Science ®Google Scholar
• https://Pubchem.Ncbi.Nlm.Nih.Gov/Compound/179344 (acessed March, 2022).
   Google Scholar
• Klein, P.; Diaz, A.; Gasalla, T.; Whitesides, J. A Review of the Pharmacology and Clinical Efficacy of Brivaracetam. Clin. Pharmacol. 2018, 10, 1–22. DOI: 10.2147/CPAA.S114072.
   PubMed Web of Science ®Google Scholar
• Larsen, C.; Shahinas, J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. J. Clin. Med. Res. 2020, 12, 129–141. DOI: 10.14740/jocmr4090.
   PubMedGoogle Scholar
• Arzimanoglou, A.; Brandl, U.; Cross, J. H.; Gil-Nagel, A.; Lagae, L.; Landmark, C. J.; Specchio, N.; Nabbout, R.; Thiele, E. A.; Gubbay, O. Epilepsy and Cannabidiol: A Guide to Treatment. Epileptic Disord. 2020, 22, 1–14. DOI: 10.1684/epd.2020.1141.
   PubMed Web of Science ®Google Scholar
• Huestis, M. A. Human Cannabinoid Pharmacokinetics. Chem. Biodivers. 2007, 4, 1770–1804. DOI: 10.1002/cbdv.200790152.
   PubMed Web of Science ®Google Scholar
• Reddy, D. S. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy. Clin. Pharmacol. Ther. 2017, 101, 182–184. DOI: 10.1002/cpt.441.
   PubMed Web of Science ®Google Scholar
• Trojnar, M. K.; Wojtal, K.; Trojnar, M. P.; Czuczwar, S. J. Stiripentol. A Novel Antiepileptic Drug. Pharmacol. Rep. 2005, 57, 154–160.
   PubMed Web of Science ®Google Scholar
• https://pubchem.ncbi.nlm.nih.gov/compound/6442177 (accessed March, 2022).
   Google Scholar
• Keam, S. J. Cenobamate: First Approval. Drugs 2020, 80, 73–78. DOI: 10.1007/s40265-019-01250-6.
   PubMed Web of Science ®Google Scholar
• Vernillet, L.; Greene, S. A.; Kamin, M. Pharmacokinetics of Cenobamate: Results from Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects. Clin. Pharmacol. Drug Dev. 2020, 9, 428–443. DOI: 10.1002/cpdd.769.
   PubMed Web of Science ®Google Scholar
• https://Go.Drugbank.Com/Drugs/DB00574 (accessed March, 2022).
   Google Scholar
• Moshé, S. L.; Perucca, E.; Ryvlin, P.; Tomson, T. Epilepsy: New Advances. Lancet 2015, 385, 884–898. DOI: 10.1016/S0140-6736(14)60456-6.
   PubMed Web of Science ®Google Scholar
• Brodie, M. J. Antiepileptic Drug Therapy the Story So Far. Seizure 2010, 19, 650–655. DOI: 10.1016/j.seizure.2010.10.027.
   PubMed Web of Science ®Google Scholar
• Löscher, W.; Schmidt, D. Modern Antiepileptic Drug Development Has Failed to Deliver: Ways out of the Current Dilemma. Epilepsia 2011, 52, 657–678. DOI: 10.1111/j.1528-1167.2011.03024.x.
   PubMed Web of Science ®Google Scholar
• Carcak, N.; Ozkara, C. Seizures and Antiepileptic Drugs: From Pathophysiology to Clinical Practice. Curr. Pharm. Des. 2017, 23, 6376–6388. DOI: 10.2174/1381612823666171115101557.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem, E. Pregabalin Pharmacology and Its Relevance to Clinical Practice. Epilepsia 2004, 45, 13–18. DOI: 10.1111/j.0013-9580.2004.455003.x.
   PubMed Web of Science ®Google Scholar
• Onakpoya, I. J.; Thomas, E. T.; Lee, J. J.; Goldacre, B.; Heneghan, C. J. Benefits and Harms of Pregabalin in the Management of Neuropathic Pain: A Rapid Review and Meta-Analysis of Randomised Clinical Trials. BMJ Open 2019, 9, e023600. DOI: 10.1136/bmjopen-2018-023600.
   PubMed Web of Science ®Google Scholar
• Arzimanoglou, A.; D’Cruz, O.; Nordli, D.; Shinnar, S.; Holmes, G. L. A Review of the New Antiepileptic Drugs for Focal-Onset Seizures in Pediatrics: Role of Extrapolation. Paediatr Drugs 2018, 20, 249–264. DOI: 10.1007/s40272-018-0286-0.
   PubMed Web of Science ®Google Scholar
• Curia, G.; Biagini, G.; Perucca, E.; Avoli, M. Lacosamide: A New Approach to Target Voltage-Gated Sodium Currents in Epileptic Disorders. CNS Drugs 2009, 23, 555–568. DOI: 10.2165/00023210-200923070-00002.
   PubMed Web of Science ®Google Scholar
• Licko, T.; Seeger, N.; Zellinger, C.; Russmann, V.; Matagne, A.; Potschka, H. Lacosamide Treatment following Status Epilepticus Attenuates Neuronal Cell Loss and Alterations in Hippocampal Neurogenesis in a Rat Electrical Status Epilepticus Model. Epilepsia 2013, 54, 1176–1185. DOI: 10.1111/epi.12196.
   PubMed Web of Science ®Google Scholar
• Wang, B.; Dawson, H.; Wang, H.; Kernagis, D.; Kolls, B. J.; Yao, L.; Laskowitz, D. T. Lacosamide Improves Outcome in a Murine Model of Traumatic Brain Injury. Neurocrit. Care 2013, 19, 125–134. DOI: 10.1007/s12028-012-9808-8.
   PubMed Web of Science ®Google Scholar
• Kim, G. H.; Byeon, J. H.; Eun, B. L. Neuroprotective Effect of Lacosamide on Hypoxic-Ischemic Brain Injury in Neonatal Rats. J. Clin. Neurol. 2017, 13, 138–143. DOI: 10.3988/jcn.2017.13.2.138.
   PubMed Web of Science ®Google Scholar
• Rosati, A.; De Masi, S.; Guerrini, R. Antiepileptic Drug Treatment in Children with Epilepsy. CNS Drugs 2015, 29, 847–863. DOI: 10.1007/s40263-015-0281-8.
   PubMed Web of Science ®Google Scholar
• Rogawski, M. A.; Hanada, T. Preclinical Pharmacology of Perampanel, a Selective Non-Competitive AMPA Receptor Antagonist. Acta Neurol. Scand. 2013, 127, 19–24. DOI: 10.1111/ane.12100.
   PubMed Web of Science ®Google Scholar
• Steinhoff, B. J.; Klein, P.; Klitgaard, H.; Laloyaux, C.; Moseley, B. D.; Ricchetti-Masterson, K.; Rosenow, F.; Sirven, J. I.; Smith, B.; Stern, J. M.; et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review: A Systematic Review. Epilepsy Behav. 2021, 118, 107939. DOI: 10.1016/j.yebeh.2021.107939.
   PubMed Web of Science ®Google Scholar
• Galiana, G. L.; Gauthier, A. C.; Mattson, R. H. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures. Drugs R D 2017, 17, 329–339. DOI: 10.1007/s40268-017-0197-5.
   PubMed Web of Science ®Google Scholar
• Elger, C.; Halász, P.; Maia, J.; Almeida, L.; Soares-da-Silva, P. Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Treatment in Adults with Refractory Partial-Onset Seizures: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study. Epilepsia 2009, 50, 454–463. DOI: 10.1111/j.1528-1167.2008.01946.x.
   PubMed Web of Science ®Google Scholar
• Łuszczki, J. J. Third-Generation Antiepileptic Drugs: Mechanisms of Action, Pharmacokinetics and Interactions. Pharmacol. Rep. 2009, 61, 197–216. DOI: 10.1016/S1734-1140(09)70024-6.
   PubMed Web of Science ®Google Scholar
• Perucca, E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? J. Epilepsy Res. 2017, 7, 61–76. DOI: 10.14581/jer.17012.
   PubMedGoogle Scholar
• Abou-khalil, B. B. W. Update on Antiepileptic Drugs 2019. Contin. Lifelong Learn. Neurol. 2019, 25, 508–536.
   Google Scholar
• Devinsky, O.; Cross, J. H.; Laux, L.; Marsh, E.; Miller, I.; Nabbout, R.; Scheffer, I. E.; Thiele, E. A.; Wright, S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N. Engl. J. Med. 2017, 376, 2011–2020. DOI: 10.1056/NEJMoa1611618.
   PubMed Web of Science ®Google Scholar
• Devinsky, O.; Patel, A. D.; Cross, J. H.; Villanueva, V.; Wirrell, E. C.; Privitera, M.; Greenwood, S. M.; Roberts, C.; Checketts, D.; VanLandingham, K. E.; Zuberi, S. M. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N. Engl. J. Med. 2018, 378, 1888–1897. DOI: 10.1056/NEJMoa1714631.
   PubMed Web of Science ®Google Scholar
• Plosker, G. L. Stiripentol: In Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome). CNS Drugs 2012, 26, 993–1001. DOI: 10.1007/s40263-012-0004-3.
   PubMed Web of Science ®Google Scholar
• Bialer, M.; Johannessen, S. I.; Levy, R. H.; Perucca, E.; Tomson, T.; White, H. S. Progress Report on New Antiepileptic Drugs: A Summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia 2017, 58, 181–221. DOI: 10.1111/epi.13634.
   PubMed Web of Science ®Google Scholar
• Latimer, D. R.; Edinoff, A. N.; Ruff, R. D.; Rooney, K. C.; Penny, K. M.; Patel, S. B.; Sabbenahalli, S.; Kaye, A. M.; Cornett, E. M.; Viswanath, O.; et al. Cenobamate, a Sodium Channel Inhibitor and Positive Allosteric Modulator of Gabaa Ion Channels, for Partial Onset Seizures in Adults: A Comprehensive Review and Clinical Implications. Neurol. Int. 2021, 13, 252–265. DOI: 10.3390/neurolint13020026.
   PubMed Web of Science ®Google Scholar
• Wiciński, M.; Puk, O.; Malinowski, B. Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug. Neurochem. Res. 2021, 46, 439–446. DOI: 10.1007/s11064-020-03188-8.
   PubMed Web of Science ®Google Scholar
• Zaccara, G.; Lattanzi, S.; Leo, A.; Russo, E. Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults. Neuropsychiatr. Dis. Treat. 2021, 17, 3447–3457. DOI: 10.2147/NDT.S281490.
   PubMed Web of Science ®Google Scholar
• Schoonjans, A.; Paelinck, B. P.; Marchau, F.; Gunning, B.; Gammaitoni, A.; Galer, B. S.; Lagae, L.; Ceulemans, B. Low-Dose Fenfluramine Significantly Reduces Seizure Frequency in Dravet Syndrome: A Prospective Study of a New Cohort of Patients. Eur. J. Neurol. 2017, 24, 309–314. DOI: 10.1111/ene.13195.
   PubMed Web of Science ®Google Scholar
• Lagae, L.; Schoonjans, A. S.; Gammaitoni, A. R.; Galer, B. S.; Ceulemans, B. A Pilot, Open-Label Study of the Effectiveness and Tolerability of Low-Dose ZX008 (Fenfluramine HCl) in Lennox-Gastaut Syndrome. Epilepsia 2018, 59, 1881–1888. DOI: 10.1111/epi.14540.
   PubMed Web of Science ®Google Scholar
• Kellogg, M. D. Measurement of Biological Material. In Clinical and Translational Science, 2nd ed.; Academic Press. Boston, MA, United States. 2017. DOI:10.1016/B978-0-12-802101-9.00008-9.
   Google Scholar
• Dong, M. W. The Essence of Modern HPLC: Advantages, Limitations, Fundamentals, and Opportunities. LCGC North Am. 2013, 31, 472–479.
   Web of Science ®Google Scholar
• Sharath, C. S.; Priyanka, G.; Dhanalakshmi, K.; Reddy, N. Switch from HPLC to UPLC: A Novel Achievement in Liquid Chromatography Technique-A Review. Int. J. Pharm. Sci. Rev. Res. 2013, 21, 237–246.
   Google Scholar
• Sonia, K.; Shree, B. B.; Lakshmi, K. S. HPTLC Method Development and Validation: An Overview. J. Pharm. Sci. Res. 2017, 9, 652–657.
   Google Scholar
• Kashid, S. K.; Tapkir, A.; Choudhari, P. Analytical Method Development and Validation for Stability Indicating Hptlc Method for Assay of Stiripentol in Bulk and Dosage Form. J. App. Pharm. Sci. Res. 2021, 3, 26–30. DOI: 10.31069/japsr.v3i4.5.
   Google Scholar
• Ivanova, S.; Todorova, V.; Dyankov, S.; Ivanov, K. High-Performance Thin-Layer Chromatography (HPTLC) Method for Identification of Meloxicam and Piroxicam. Processes 2022, 10, 394. DOI: 10.3390/pr10020394.
   Web of Science ®Google Scholar
• Rushikesh, S.; Aniket, L.; A, S. Hyphenated Techniques, an Important Tool for Force Degradation Study. Acta Sci. Pharm. Sci. 2020, 4, 23–28.
   Google Scholar
• Beccaria, M.; Cabooter, D. Current Developments in LC-MS for Pharmaceutical Analysis. Analyst 2020, 145, 1129–1157. DOI: 10.1039/c9an02145k.
   PubMed Web of Science ®Google Scholar
• Charde, M.; Shinde, M.; Welankiwar, A.; Jitendra, K. Development of Analytical and Stability Testing Method for Vitamin a Palmitate Formulation. Int. J. Pharm. Chem. 2015, 5, 104–114. DOI: 10.7439/ijpc.
   Google Scholar
• ALSaeedy, M.; Al-Adhreai, A.; Öncü-Kaya, E. M.; Şener, E. An Overview of Advances in the Chromatography of Drugs Impurity Profiling. Crit. Rev. Anal. Chem. 2022, 52, 1–17. DOI: 10.1080/10408347.2022.2032587.
   PubMedGoogle Scholar
• Dongre, V. G.; Ghugare, P. D.; Karmuse, P.; Singh, D.; Jadhav, A.; Kumar, A. Identification and Characterization of Process Related Impurities in Chloroquine and Hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR. J. Pharm. Biomed. Anal. 2009, 49, 873–879. DOI: 10.1016/j.jpba.2009.01.013.
   PubMed Web of Science ®Google Scholar
• Corcoran, O.; Spraul, M. LC-NMR-MS in Drug Discovery. Drug Discov. Today 2003, 8, 624–631. DOI: 10.1016/S1359-6446(03)02749-1.
   PubMed Web of Science ®Google Scholar
• Leibfritz, D.; Willmann, J.; Thiele, H. Combined Reversed Phase HPLC, Mass Spectrometry, and NMR Spectroscopy for a Fast Separation and Efficient Identification of Phosphatidylcholines. J. Biomed. Biotechnol. 2011, 2011, 1–8. DOI: 10.1155/2011/385786.
   Google Scholar
• Alves, G.; Figueiredo, I.; Castel-Branco, M.; Loureiro, A.; Falcão, A.; Caramona, M. Simultaneous and Enantioselective Liquid Chromatographic Determination of Eslicarbazepine Acetate, S-Licarbazepine, R-Licarbazepine and Oxcarbazepine in Mouse Tissue Samples Using Ultraviolet Detection. Anal. Chim. Acta. 2007, 596, 132–140. DOI: 10.1016/j.aca.2007.05.056.
   PubMed Web of Science ®Google Scholar
• Thomas, S.; Paul, S. K.; Joshi, S. C.; Kumar, V.; Agarwal, A.; Vir, D. Identification, Synthesis and Characterization of an Unknown Process Related Impurity in Eslicarbazepine Acetate Active Pharmaceutical Ingredient by LC/ESI-IT/MS, 1H, 13C and 1H-1H COSY NMR. J. Pharm. Anal. 2014, 4, 339–344. DOI: 10.1016/j.jpha.2013.08.004.
   PubMedGoogle Scholar
• Husain, A.; Iram, F.; Siddiqui, A. A.; Almutairi, S. M.; Mohammed, O. B.; Khan, S. A.; Azmi, S. N. H.; Rahman, N. Identification of Metabolic Pathways Involved in the Biotransformation of Eslicarbazepine Acetate Using UPLC-MS/MS, Human Microsomal Enzymes and in Silico Studies. J. King Saud. Univ. – Sci. 2021, 33, 101281. DOI: 10.1016/j.jksus.2020.101281.
   Web of Science ®Google Scholar
• Mone, M. K.; Chandrasekhar, K. B. Development of Liquid Chromatographic Enantiomer Separation Methods and Validation for the Estimation of (R)-Enantiomer in Eslicarbazepine Acetate. J. Pharm. Biomed. Anal. 2011, 54, 248–251. DOI: 10.1016/j.jpba.2010.08.015.
   PubMed Web of Science ®Google Scholar
• Srinivas, M.; Avupati, N. R.; Sait, S.; Mukkanti, K. Stability Indicating HPLC Method for the Determination of Eslicarbazepine Acetate and Its Impurities in Bulk Drugs and Pharmaceutical Dosage Forms. J. Liq. Chromatogr. Relat. Technol. 2012, 35, 1550–1564. DOI: 10.1080/10826076.2011.619043.
   Web of Science ®Google Scholar
• Fortuna, A.; Sousa, J.; Alves, G.; Falcão, A.; Soares-Da-Silva, P. Development and Validation of an HPLC-UV Method for the Simultaneous Quantification of Carbamazepine, Oxcarbazepine, Eslicarbazepine Acetate and Their Main Metabolites in Human Plasma. Anal. Bioanal. Chem. 2010, 397, 1605–1615. DOI: 10.1007/s00216-010-3673-0.
   PubMed Web of Science ®Google Scholar
• Fortuna, A.; Bicker, J.; Alves, G.; Falcão, A.; Soares-Da-Silva, P. A Chiral HPLC-UV Method for the Quantification of Dibenz[b,f]Azepine-5- Carboxamide Derivatives in Mouse Plasma and Brain Tissue: Eslicarbazepine Acetate, Carbamazepine and Main Metabolites. J. Sep. Sci. 2011, 34, 1391–1401. DOI: 10.1002/jssc.201100099.
   PubMed Web of Science ®Google Scholar
• Iram, F.; Alam, P.; Siddiqui, N. A.; Alqasoumi, S. I.; Siddiqui, A. A.; Khan, S. A.; Husain, A. Development of a Stress Induced Validated UPLC-PDA Method for the Analysis of Eslicarbazepine Acetate. Saudi Pharm. J. 2018, 26, 286–291. DOI: 10.1016/j.jsps.2017.11.009.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu, V.; Rao, D. R.; Uma Maheswari, B. N.; Das, S. K.; Krishnaiah, A. Development and Validation of a Stability-Indicating RP - HPLC Method for Determination of Lacosamide. Res. J. Pharm. Biol. Chem. Sci. 2011, 2, 1–11. DOI: 10.37285/ijpsn.2019.12.5.3.
   Google Scholar
• Mohamed, S.; Candela, C.; Riva, R.; Contin, M. Simple and Rapid Validated HPLC-Fluorescence Determination of Perampanel in the Plasma of Patients with Epilepsy. Pract. Lab. Med. 2018, 10, 15–20. DOI: 10.1016/j.plabm.2017.11.003.
   PubMedGoogle Scholar
• Ramisetti, N. R.; Kuntamukkala, R.; Lakshetti, S.; Sripadi, P. Identification and Characterization of Stress Degradants of Lacosamide by LC-MS and ESI-Q-TOF-MS/MS: Development and Validation of a Stability Indicating RP-HPLC Method. J. Pharm. Biomed. Anal. 2014, 95, 256–264. DOI: 10.1016/j.jpba.2014.03.010.
   PubMed Web of Science ®Google Scholar
• Charagondla, K. A Validated Chiral Liquid Chromatographic Method for the Enantiomeric Separation of Lacosamide Drug Product and Its Dosage Forms. J. Chromatogr. Sep. Tech. 2015, 06, 280. DOI: 10.4172/2157-7064.1000280.
   Google Scholar
• Hassib, S. T.; Hashem, H. M. A.; Mahrouse, M. A.; Mostafa, E. A. A Validated Reversed-Phase High-Performance Liquid Chromatography Method for Simultaneous Determination of Five Antiepileptic Drugs Used in the Treatment of Lennox-Gastaut Syndrome in Their Pharmaceutical Dosage Forms. Asian J. Pharm. Clin. Res. 2018, 11, 167–173. DOI: 10.22159/ajpcr.2018.v11i5.24143.
   Google Scholar
• Patil, S. N.; Agrawal, P. N.; Kadam, A.; Manish, M.; Askshay, S. Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Lacosamide in Bulk and Its Pharmaceutical Formulations. Int. J. Pharm. Sci. Rev. Res. 2014, 28, 164–168. DOI: 10.4236/ajac.2012.35050.
   Google Scholar
• Valarmathi, R.; Senthamarai, R.; Akilandeswari, S.; Banu, S. F.; Saratha, R. Newer Analytical Validation of Lacosamide in Bulk and Their Tablet Dosage Form by RP-HPLC. World J. Pharm. Pharm. Sci. 2015, 4, 1083–1091.
   Google Scholar
• Mohamed, F. A.; Ali, M. F. B.; Rageh, A. H.; Mostafa, A. M. Highly Sensitive UHPLC–DAD Method for Simultaneous Determination of Two Synergistically Acting Antiepileptic Drugs; Levetiracetam and Lacosamide: Application to Pharmaceutical Tablets and Human Urine. Biomed. Chromatogr. 2019, 33, 1–11. DOI: 10.1002/bmc.4554.
   Web of Science ®Google Scholar
• Nazma, S.; Yasaswini, P.; Supraja, M. S.; Vijayalakshmi, M.; Nalluri, B. N. Development and Validation of RP-HPLC Method for the Estimation of Lacosamide in Bulk and Parenteral Dosage Form. Int. J. Res. Pharm. Chem. 2015, 5, 355–360.
   Google Scholar
• Baksam, V. K.; Saritha, N.; Mohan, S. K.; Shandilya, S.; Kumar, P. Identification and Characterization of Prothionamide Degradation Impurities by Mass Spectrometry, NMR Spectroscopy, and Ultra High Performance Liquid Chromatography Method Development. J. Sep. Sci. 2021, 44, 2078–2088. DOI: 10.1002/jssc.202100050.
   PubMed Web of Science ®Google Scholar
• Chauhan, A. Y.; Patel, C. J.; Patel, M. M. DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF LACOSAMIDE AND ITS RELATED SUBSTANCE IN PARENTERAL DOSAGE FORM. World J. Pharm. Res. 2018, 7, 277–291. DOI: 10.20959/wjpr20188-11823.
   Google Scholar
• Raul, S. K.; Mahapatra, A. K.; Ravi Kumar, B. V. V.; Patnaik, A. K. Stability Indicating RP-HPLC Method for the Estimation of Lacosamide in Bulk and Pharmaceutical Dosage Form. J. Chem. Pharm. Res 2013, 5, 732–739.
   Google Scholar
• Patel, A.; Suhagia, B. N.; Patwari, A. Stability Indicating Assay Method for Quantification of Lacosamide in Bulk and Its Pharmaceutical Dosage Form and Characterization of Major Degradation Products. Int. J. Pharm. Pharm. Sci. 2014, 6, 593–599.
   Google Scholar
• Mahesh, H. R. K.; Babu, S. K. Quantitative Estimation of Related Compounds of Lacosamide in Oral Solution by Using Reverse Phase HPLC. Der Pharm. Lett. 2015, 7, 285–291.
   Google Scholar
• Carona, A.; Bicker, J.; Silva, R.; Silva, A.; Santana, I.; Sales, F.; Falcão, A.; Fortuna, A. HPLC Method for the Determination of Antiepileptic Drugs in Human Saliva and Its Application in Therapeutic Drug Monitoring. J. Pharm. Biomed. Anal. 2021, 197, 113961. DOI: 10.1016/j.jpba.2021.113961.
   PubMed Web of Science ®Google Scholar
• Molleti, S.; Rao, V.; Jayaveera, K. N. Stability Indicating RP-UPLC Method for the Determination of Lacosamide and Its Impurities in Bulk Drugs and Its Pharmaceutical Dosage Forms. Der. Pharma. Chem. 2013, 5, 81–89.
   Google Scholar
• Srivastava, D. R. K. Determinitaion of Benzaldehyde Genotoxic Impurity in Lacosamide Drug Substances Using HPLC Technique. WJPPS 2017, 6, 1844–1851. DOI: 10.20959/wjpps20177-9630.
   Google Scholar
• Kalyan Chakravarthy, V.; Gowri Shankar, D. HPLC Method for Determination of Lacosamide S(-)Enantiomer in Bulk and Pharmaceutical Formulation. Rasayan J. Chem. 2011, 4, 744–752.
   Google Scholar
• Korany, M. A.; Mahgoub, H.; Haggag, R. S.; Ragab, M. A. A.; Elmallah, O. A. Green Gas Chromatographic Stability-Indicating Method for the Determination of Lacosamide in Tablets. Application to In-Vivo Human Urine Profiling. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2018, 1083, 75–85. DOI: 10.1016/j.jchromb.2018.02.033.
   PubMed Web of Science ®Google Scholar
• Kalyan Chakravarthy, Y.; Gowri Sankar, D. Stability Indicating HPLC Method for Determination of Lacosamide and Its Degradants/Impurities in Bulk and Pharmaceutical Formulation. Rasayan J. Chem. 2012, 5, 293–310.
   Google Scholar
• Sabença, R.; Bicker, J.; Silva, R.; Carona, A.; Silva, A.; Santana, I.; Sales, F.; Falcão, A.; Fortuna, A. Development and Application of an HPLC-DAD Technique for Human Plasma Concentration Monitoring of Perampanel and Lamotrigine in Drug-Resistant Epileptic Patients. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2021, 1162, 122491. DOI: 10.1016/j.jchromb.2020.122491.
   PubMed Web of Science ®Google Scholar
• Mano, Y.; Takenaka, O.; Kusano, K. High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Perampanel, a Novel α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Antagonist in Human Plasma. J. Pharm. Biomed. Anal. 2015, 107, 56–62. DOI: 10.1016/j.jpba.2014.12.018.
   PubMed Web of Science ®Google Scholar
• Franco, V.; Marchiselli, R.; Fattore, C.; Tartara, E.; De Sarro, G.; Russo, E.; Perucca, E. Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma. Ther. Drug Monit. 2016, 38, 744–750. DOI: 10.1097/FTD.0000000000000350.
   PubMed Web of Science ®Google Scholar
• Paul, D.; Allakonda, L.; Sahu, A.; Surendran, S.; Satheeshkumar, N. Pharmacokinetics and Brain Uptake Study of Novel AMPA Receptor Antagonist Perampanel in SD Rats Using a Validated UHPLC-QTOF-MS Method. J. Pharm. Biomed. Anal. 2018, 149, 234–241. DOI: 10.1016/j.jpba.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Patel, C. J.; Patel, S. S.; Patel, M. M. Method Development and Stability Study by Chromatographic Method for Perampanel in API and Tablet Dosage Form. Int. J. Pharm. Drug Anal. 2017, 5, 229–240.
   Google Scholar
• Mano, Y.; Takenaka, O.; Kusano, K. HPLC with Fluorescence Detection Assay of Perampanel, a Novel AMPA Receptor Antagonist, in Human Plasma for Clinical Pharmacokinetic Studies. Biomed. Chromatogr. 2015, 29, 1589–1593. DOI: 10.1002/bmc.3463.
   PubMed Web of Science ®Google Scholar
• Ohkubo, S.; Akamine, Y.; Ohkubo, T.; Kikuchi, Y.; Miura, M. Quantification of the Plasma Concentrations of Perampanel Using High-Performance Liquid Chromatography and Effects of the CYP3A4* 1G Polymorphism in Japanese Patients. J. Chromatogr. Sci. 2020, 58, 915–921. DOI: 10.1093/chromsci/bmaa060.
   PubMed Web of Science ®Google Scholar
• Saida, S. J.; Muthuchamy, M.; Kaliyaperumal, M.; Rumalla, C. S.; Yanaka, R.; Venkat Rao, S. Isolation and Spectral Characterization of Degradation Impurity in Perampanel Drug Substance Using UPLC-MS and NMR Spectroscopy: Validation of Assay Method by UPLC. Asian J. Chem. 2018, 30, 2215–2219. DOI: 10.14233/ajchem.2018.21405.
   Google Scholar
• Charlier, B.; Coglianese, A.; Operto, F. F.; De Rosa, F.; Mensitieri, F.; Coppola, G.; Filippelli, A.; Dal Piaz, F.; Izzo, V. Perampanel Dosage in Plasma Samples: Development and Validation of a Novel HPLC Method with Combined UV-Fluorescence Detection. J. Pharm. Biomed. Anal. 2021, 204, 114252. DOI: 10.1016/j.jpba.2021.114252.
   PubMed Web of Science ®Google Scholar
• Mano, Y. An Inter-Laboratory Cross-Validation Study for the Determination of Perampanel in Human Plasma by Liquid Chromatography Assays. Biomed. Chromatogr. 2016, 30, 2067–2069. DOI: 10.1002/bmc.3764.
   PubMed Web of Science ®Google Scholar
• Tůma, P.; Bursová, M.; Sommerová, B.; Horsley, R.; Čabala, R.; Hložek, T. Novel Electrophoretic Acetonitrile-Based Stacking for Sensitive Monitoring of the Antiepileptic Drug Perampanel in Human Serum. J. Pharm. Biomed. Anal. 2018, 160, 368–373. DOI: 10.1016/j.jpba.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Meirinho, S.; Campos, G.; Rodrigues, M.; Fortuna, A.; Falcão, A.; Alves, G. Salting-out Assisted Liquid–Liquid Extraction Method Optimized by Design of Experiments for the Simultaneous High-Performance Liquid Chromatography Analysis of Perampanel and Stiripentol in Mouse Matrices. J. Sep. Sci. 2020, 43, 4289–4304. DOI: 10.1002/jssc.202000656.
   PubMed Web of Science ®Google Scholar
• Elhawi, M. M.; Hassan, W. S.; El-Sheikh, R.; El-Sayed, H. M. Multivariate Analysis of Perampanel in Pharmaceutical Formulations Using RP-HPLC. Chromatographia 2020, 83, 1335–1343. DOI: 10.1007/s10337-020-03950-8.
   Web of Science ®Google Scholar
• Karavadi, T. M.; Challa, B. R. Bioanalytical Method Development and Validation of Pregabalin in Rat Plasma by Solid Phase Extraction with HPLC-MS/MS: Application to a Pharmacokinetic Study. J. Liq. Chromatogr. Relat. Technol. 2014, 37, 130–144. DOI: 10.1080/10826076.2012.738617.
   Web of Science ®Google Scholar
• Harnisch, H.; Chien, Y.; han, G. K.; Scriba, E. Capillary Electrophoresis Method for the Chiral Purity Determination of Pregabalin Derivatized with Dansyl Chloride. Chromatographia 2018, 81, 719–725. DOI: 10.1007/s10337-018-3495-3.
   Web of Science ®Google Scholar
• Chennuru, L. N.; Choppari, T.; Nandula, R. P.; Zhang, T.; Franco, P. Direct Separation of Pregabalin Enantiomers Using a Zwitterionic Chiral Selector by High Performance Liquid Chromatography Coupled to Mass Spectrometry and Ultraviolet Detection. Molecules 2016, 21, 1578. DOI: 10.3390/molecules21111578.
   PubMed Web of Science ®Google Scholar
• Prakash, L.; Himaja, M.; Ramakrishna Yadav, B.; Maheshwara Reddy, A. Cost-Effective Isolation of a Process Impurity of Pregabalin. Sci. Pharm. 2015, 83, 453–463. DOI: 10.3797/scipharm.1501-16.
   PubMedGoogle Scholar
• Rao, S. N.; Somaiah, S.; Ravisankar, T.; Babu, K. S. Synthesis and Charecterization of Impurities of an Anticonvulsant Drug. Lamotrigine. Int. J. Pharm. Pharm. Sci. 2012, 4, 133–136.
   Google Scholar
• Gujral, R. S.; Haque, S. M.; Shanker, P. A Sensitive Spectrophotometric Method for the Determination of Pregabalin in Bulk, Pharmaceutical Formulations and in Human Urine Samples. Int. J. Biomed. Sci. 2009, 5, 421–427.
   PubMedGoogle Scholar
• Balaji, J.; Ramachandra, B.; Naidu, N. V. S. Analytical RP-HPLC Method for Development and Validation of Pregabalin in Bulk and the Determination of Pregabalin in Capsule Dosage Form. Int. J. Innov. Res. Sci. Eng. Technol. 2007, 3, 11094–11098.
   Google Scholar
• Martinc, B.; Grabnar, I.; Mrhar, A.; Vovk, T. Rapid High-Performance Liquid Chromatography Method for Determination of Pregabalin in a Pharmaceutical Dosage Form Following Derivatization with Fluorescamine. J. AOAC Int. 2010, 93, 1069–1076.
   PubMed Web of Science ®Google Scholar
• Ponnekanti, K.; Sunitha, K.; Ganapaty, S. Development and Validation of New Rp-Hplc Method for Simultaneous Estimation of Methylcobalamin, Epalrestat and Pregabalin in Bulk and Pharmaceutical Dosage Form. RJPT 2021, 14, 5097–5100. DOI: 10.52711/0974-360X.2021.00888.
   Web of Science ®Google Scholar
• Sreekanth, D.; Ramya, P.; Vishwanadham, Y.; Vanitha, R. Development and Method Validation of RP-HPLC for Simultaneous Determination of Pregabalin and Methylcobalamin in Pure and Pharmaceutical Dosage Form. Asia. J. Res. Chem. 2017, 10, 557. DOI: 10.5958/0974-4150.2017.00092.X.
   Google Scholar
• Patel, R. K.; Dholakiya, S.; Vaidya, S. a.; G, N. A Novel Spectrophotometric and RP-HPLC Methods for Determination of Nortriptyline Hydrochloride and Pregabalin in Tablets - Pharmaceutical Research and Allied Sciences. Int. J. Pharm. Res. Allied Sci. 2020, 9, 1–9.
   Web of Science ®Google Scholar
• Chen, X.; Zhang, D.; Deng, J.; Fu, X. Determination of Optical Impurity of Pregabalin by HPLC With Pre-Column Chiral Derivatization. J. Chromatogr. Sci. 2008, 46, 42–44. DOI: 10.1093/chromsci/46.1.42.
   PubMed Web of Science ®Google Scholar
• Mohan, A.; Rajkumar, J.; Bhavya, B.; Ashok Kumar, T. A. RP-HPLC Method Development and Validation for the Simultaneous Quantitative Estimation of Pregabalin, Mecobalamin and Alpha Lipoic Acid in Capsules. Int. J. Pharm. Pharm. Sci. 2014, 6, 270–277.
   Google Scholar
• Ahmadkhaniha, R.; Mottaghi, S.; Zargarpoor, M.; Souri, E. Validated HPLC Method for Quantification of Pregabalin in Human Plasma Using 1-Fluoro-2,4-Dinitrobenzene as Derivatization Agent. Chromatogr. Res. Int. 2014, 2014, 1–6. DOI: 10.1155/2014/450461.
   Google Scholar
• Gelani, H. D.; Chauhan, P. P.; Shah, S. K. Practical Implication of Chromatographic Method for Estimation of Aceclofenac and Pregabalin in Bulk and Pharmaceutical Dosage Forms. Chromatogr. Res. Int. 2014, 2014, 1–5. DOI: 10.1155/2014/643027.
   Google Scholar
• Udayalakshmi, P.; Muthukumaran, M.; Krishnanmoorthy B. Simultaneous Estimation of Pregabalin and Methylcobalamin BYRP-HPLC in Bulk Drug and Combined Tablet Dosasge Form. Int. J. Pharm. Health Care Res. 2014, 2, 74–80.
   Google Scholar
• Kannapan, N.; Nayak, S. P.; Venkatachalam, V. P. Analytical RP-HPLC Method for Development and Validation of Pregabalin and Methylcobalamine in Combined Capsule Formulation Analytical RP-HPLC Method for Development and Validation of Pregabalin and Methylcobalamine in Combined Capsule Formulation. J. Appl. Chem. Res. 2010, 13, 85–89.
   Google Scholar
• Kavitha, M.; Rajasekhar, A. A Validated HPLC Method for the Analysis of Pregabalin and Methylcobalamin in Bulk and Pharmaceutical Formulation. Pharm. Glob. Int. J. Compr. Pharm. 2013, 7, 1–5.
   Google Scholar
• Atta, A. M.; Mostafa, S.; Salama, I.; Gomaa, M. S. A New HPLC Method for Simultaneous Determination of Atenolol and Pregabalin in Dosage Forms and in Human Urine. Int. J. Pharm. Chem. Biol. Sci. 2016, 6, 48–61.
   Google Scholar
• Seema, A.; Jeeja, P.; Ashish, J. Development and Validation of HPLC Method for Estimation of Pregabalin in Bulk & Capsule Dosage Form. Pharm. Anal. Acta 2016, 7, 6. DOI: 10.4172/2153-2435.1000492.
   Google Scholar
• Douša, M.; Gibala, P.; Lemr, K. Liquid Chromatographic Separation of Pregabalin and Its Possible Impurities with Fluorescence Detection after Postcolumn Derivatization with O-Phtaldialdehyde. J. Pharm. Biomed. Anal. 2010, 53, 717–722. DOI: 10.1016/j.jpba.2010.04.008.
   PubMed Web of Science ®Google Scholar
• Akther, H.; Masud Morshed, M.; Mohaiminul Islam, M.; Hassan, J.; Barna Piyal Barua, T. B. E. Development of a Method and Its Validation for Estimation of Pregabaline in Pharmaceutical and Bulk Formulation. Biomed. Sci. Today 2015, 22,1–8.
   PubMedGoogle Scholar
• Souri, E.; Eskandari, M.; Barazandeh Tehrani, M.; Adib, N.; Ahmadkhaniha, R. HPLC Determination of Pregabalin in Bulk and Pharmaceutical Dosage Forms After Derivatization With 1-Fluoro-2,4-Dinitrobenzene. Asian J. Chem. 2013, 25, 7332–7336. DOI: 10.14233/ajchem.2013.14624.
   Google Scholar
• Jadhav, A. S.; Pathare, D. B.; Shingare, M. S. Validated Enantioselective LC Method, with Precolumn Derivatization With Marfey’s Reagent, for Analysis of the Antiepileptic Drug Pregabalin in Bulk Drug Samples. Chroma 2007, 65, 253–256. DOI: 10.1365/s10337-006-0152-z.
   Web of Science ®Google Scholar
• Khanage, S. G.; Kale, D. S.; Mohite, P. B.; Deshmukh, V. K. Reversed Phase High Performance Liquid Chromatographic Method for Simultaneous Estimation of Pregabalin and Aceclofenac in Tablet Formulation (Acenac-N). J. Reports Pharm. Sci. 2014, 3, 184–192.
   Google Scholar
• Arayne, M. S. Monitoring of Pregabalin in Pharmaceutical Formulations and Human Serum Using UV and RP-HPLC Techniques: Application to Dissolution Test Method. Pharm. Anal. Acta 2014, 05, 287. DOI: 10.4172/2153-2435.1000287.
   Google Scholar
• Potluri, H.; Battula, S. R.; Yeturu, S. Validated Stability Indicating RP-HPLC Method for Simultaneous Determination of Nortriptyline and Pregabalin in Bulk and Combined Dosage Formulations. J. Chil. Chem. Soc. 2017, 62, 3490–3495. DOI: 10.4067/S0717-97072017000200013.
   Web of Science ®Google Scholar
• Douša, M.; Srbek, J.; Rádl, S.; Černý, J.; Klecán, O.; Havlíček, J.; Tkadlecová, M.; Pekárek, T.; Gibala, P.; Nováková, L. Identification, Characterization, Synthesis and HPLC Quantification of New Process-Related Impurities and Degradation Products in Retigabine. J. Pharm. Biomed. Anal. 2014, 94, 71–76. DOI: 10.1016/j.jpba.2014.01.042.
   PubMed Web of Science ®Google Scholar
• Narmada, P.; Vijaya Lakshmi, G.; Nalini, G.; Gowtham, Y.; Suhasini, B.; Jogi, K. V. RP-HPLC Method Development and Validation for the Determination of Methylcobalamin and Pregabalin in Combined Capsule Dosage Form. Int. J. Res. Pharm. Sci. 2013, 4, 25–29.
   Google Scholar
• Mathesan, R.; Alexander, S.; Shankar, M.; Florance, E.; Senthilkumar, R. Method Development and Validation of Aceclofenac and Pregabalin in Marketed Formulation by UPLC Method. Acta Biomed. Sci. 2020, 7, 25–30. DOI: 10.21276/abs.2020.7.1.5.
   Google Scholar
• Ashutosh Kumar, S.; Debnath, M.; Seshagiri Rao, J. V. L. N.; Gowri Sankar, D. Stability Indicating Analytical Method Development and Validation for Simultaneous Estimation of Pregabalin, Mecobalamin and Alpha Lipoic Acid in Bulk as Well as in Pharmaceutical Dosage Form by Using RP-HPLC. Res. J. Pharm. Technol. 2014, 7, 1004–1013.
   Google Scholar
• ANNAPURNA, M. M.; KUMAR, B. S. P.; GOUTAM, S. V.; SRINIVAS, L. Stability Indicating Liquid Chromatographic Method for the Quantitative Determination of Rufinamide in Pharmaceutical Dosage Forms. J. Drug Deliv. Ther 2012, 2, 167–174. DOI: 10.22270/jddt.v2i4.253.
   Google Scholar
• Annapurna, M. M.; Madhuri, V. L.; Valli, D. S. New Stability Indicating Liquid Chromatographic Method for the Determination of Eplerenone in the Presence of Internal Standard. Asian J. Pharm. 2018, 12, S189–S194.
   Web of Science ®Google Scholar
• Contin, M.; Mohamed, S.; Candela, C.; Albani, F.; Riva, R.; Baruzzi, A. Simultaneous HPLC-UV Analysis of Rufinamide, Zonisamide, Lamotrigine, Oxcarbazepine Monohydroxy Derivative and Felbamate in Deproteinized Plasma of Patients with Epilepsy. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2010, 878, 461–465. DOI: 10.1016/j.jchromb.2009.11.039.
   PubMed Web of Science ®Google Scholar
• Dalvi, A. V.; Uppuluri, C. T.; Bommireddy, E. P.; Ravi, P. R. Design of Experiments-Based RP – HPLC Bioanalytical Method Development for Estimation of Rufinamide in Rat Plasma and Brain and Its Application in Pharmacokinetic Study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2018, 1102–1103, 74–82. DOI: 10.1016/j.jchromb.2018.10.014.
   PubMed Web of Science ®Google Scholar
• Vladimir, V. F. 済無No Title No Title No Title. Gastron. Ecuatoriana Tur. Local 1967, 1, 5–24.
   Google Scholar
• Gáll, Z.; Vancea, S.; Dogaru, M. T.; Szilágyi, T. Liquid Chromatography-Mass Spectrometric Determination of Rufinamide in Low Volume Plasma Samples. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 940, 42–46. DOI: 10.1016/j.jchromb.2013.07.014.
   PubMed Web of Science ®Google Scholar
• Ganorkar, S. B.; Chaudhari, S. R.; Bobade, P. S.; Pawar, S. H.; Shirkhedkar, A. A. HPLC–PDA Identification and Resolution of Rufinamide Forced Degradation Impurities: A Congregated Chemometric Expedite Optimization Coupled With Factorials and Desirability. Biomed. Chromatogr. 2022, 36, e5345. DOI: 10.1002/bmc.5345.
   PubMed Web of Science ®Google Scholar
• Geetha, M.; Sait, S.; Sripal Reddy, P. A Stability Indicating UPLC Method for the Estimation of Related Substances, Assay and Dissolution of Rufinamide. Asian J. Chem. 2013, 25, 9775–9778. DOI: 10.14233/ajchem.2013.15314.
   Google Scholar
• Hassib, S. T.; Hashem, H. M. A.; Mahrouse, M. A.; Mostafa, E. A. Development and Bio-Analytical Validation of Chromatographic Determination Method of Rufinamide in Presence of Its Metabolite in Human Plasma. J. Chromatogr. Sci. 2021, 59, 458–464. DOI: 10.1093/chromsci/bmaa142.
   PubMed Web of Science ®Google Scholar
• Hassib, S. T.; Hashem, H. M. A.; Mahrouse, M. A.; Mostafa, E. A. Determination of Rufinamide in the Presence of 1-[(2,6-Difluorophenyl)Methyl]-1H-1,2,3-Triazole-4 Carboxylic Acid Using RP-HPLC and Derivative Ratio Methods as Stability Indicating Assays to Be Applied on Dosage Form. J AOAC Int. 2020, 103, 1215–1222. DOI: 10.1093/jaoacint/qsaa020.
   PubMed Web of Science ®Google Scholar
• Sai Pavan Kumar, B.; Mathrusri Annapurna, M.; Pavani, S. Development and Validation of a Stability Indicating RP-HPLC Method for the Determination of Rufinamide. J. Pharm. Anal. 2013, 3, 66–70. DOI: 10.1016/j.jpha.2012.08.003.
   PubMedGoogle Scholar
• Salunke, N.; Thipparaboina, R.; Chavan, R. B.; Lodagekar, A.; Mittapalli, S.; Nangia, A.; Shastri, N. R. Rufinamide: Crystal Structure Elucidation and Solid State Characterization. J. Pharm. Biomed. Anal. 2018, 149, 185–192. DOI: 10.1016/j.jpba.2017.11.003.
   PubMed Web of Science ®Google Scholar
• Parashar, V.; Todkar, M.; Shaikh, F.; Reddy, S.; Mehra, V.; Sinha, S. Validated Liquid Chromatographic Method for Quantitative Determination of Rufinamide Active Pharmaceutical Ingredient Form and Its Impurities. Pharm. Methods 2013, 4, 6–10. DOI: 10.1016/j.phme.2013.08.001.
   Google Scholar
• Singh, J.; Sangwan, S.; Grover, P.; Mehta, L.; Kiran, D.; Goyal, A. Analytical Method Development and Validation for Assay of Rufinamide Drug. JPTRM 2013, 1, 191–203. DOI: 10.15415/jptrm.2013.12012.
   Google Scholar
• Mahamuni, B. S.; Srinivas, R.; Talluri, M. V. K. Characterization of Forced Degradation Products of Rufinamide by LC/QTOF/MS/MS, NMR and IR Studies. Anal. Chem. Lett. 2018, 8, 405–415. DOI: 10.1080/22297928.2018.1438315.
   Google Scholar
• Mazzucchelli, I.; Rapetti, M.; Fattore, C.; Franco, V.; Gatti, G.; Perucca, E. Development and Validation of an HPLC-UV Detection Assay for the Determination of Rufinamide in Human Plasma and Saliva. Anal. Bioanal. Chem. 2011, 401, 1013–1021. DOI: 10.1007/s00216-011-5126-9.
   PubMed Web of Science ®Google Scholar
• Meirinho, S.; Rodrigues, M.; Fortuna, A.; Falcão, A.; Alves, G. Novel Bioanalytical Method for the Quantification of Rufinamide in Mouse Plasma and Tissues Using HPLC-UV: A Tool to Support Pharmacokinetic Studies. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2019, 1124, 340–348. DOI: 10.1016/j.jchromb.2019.06.021.
   PubMed Web of Science ®Google Scholar
• Patel, A.; Patwari, A.; Suhagia, B. Development of a Validated Stability-Indicating HPTLC Method for Rufinamide in Bulk and Its Pharmaceutical Dosage Form. J. Chromatogr Sci. 2014, 52, 1294–1301. DOI: 10.1093/chromsci/bmt171.
   PubMed Web of Science ®Google Scholar
• Rahman, H.; Manirul Haque, S. Development and Validation of Chromatographic and Spectrophotometric Methods for the Quantitation of Rufinamide in Pharmaceutical Preparations. Turk. J. Pharm. Sci. 2022, 19, 267–272. DOI: 10.4274/tjps.galenos.2021.37043.
   PubMed Web of Science ®Google Scholar
• Jewell, A.; Brookes, A.; Feng, W.; Ashford, M.; Gellert, P.; Butler, J.; Fischer, P. M.; Scurr, D. J.; Stocks, M. J.; Gershkovich, P. Distribution of a Highly Lipophilic Drug Cannabidiol into Different Lymph Nodes following Oral Administration in Lipidic Vehicle. Eur. J. Pharm. Biopharm. 2022, 174, 29–34. DOI: 10.1016/j.ejpb.2022.03.014.
   PubMed Web of Science ®Google Scholar
• Xu, S.; Zhang, H.; Li, C. Z.; Lai, P. S.; Wang, G.; Chan, Y. S.; Cheng, S. H.; Chen, X. Cannabidiol Promotes Fin Regeneration and Reduces Apoptosis in Zebrafish Embryos. J. Funct. Foods 2021, 86, 104694. DOI: 10.1016/j.jff.2021.104694.
   Web of Science ®Google Scholar
• Reber, J. D.; Karschner, E. L.; Seither, J. Z.; Knittel, J. L.; Walterscheid, J. P. Screening and Confirmation Methods for the Qualitative Identification of Nine Phytocannabinoids in Urine by LC-MS/MS. Clin. Biochem. 2021, 98, 54–62. DOI: 10.1016/j.clinbiochem.2021.09.005.
   PubMed Web of Science ®Google Scholar
• Izgelov, D.; Davidson, E.; Barasch, D.; Regev, A.; Domb, A. J.; Hoffman, A. Pharmacokinetic Investigation of Synthetic Cannabidiol Oral Formulations in Healthy Volunteers. Eur. J. Pharm. Biopharm. 2020, 154, 108–115. DOI: 10.1016/j.ejpb.2020.06.021.
   PubMed Web of Science ®Google Scholar
• Fraguas-Sánchez, A. I.; Fernández-Carballido, A.; Martin-Sabroso, C.; Torres-Suárez, A. I. Stability Characteristics of Cannabidiol for the Design of Pharmacological, Biochemical and Pharmaceutical Studies. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2020, 1150, 122188. DOI: 10.1016/j.jchromb.2020.122188.
   PubMed Web of Science ®Google Scholar
• Ocque, A. J.; Hagler, C. E.; DiFrancesco, R.; Lombardo, J.; Morse, G. D. Development and Validation of an Assay to Measure Cannabidiol and Δ9-Tetrahydrocannabinol in Human EDTA Plasma by UHPLC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2019, 1112, 56–60. DOI: 10.1016/j.jchromb.2019.03.002.
   PubMed Web of Science ®Google Scholar
• Gul, W.; Gul, S. W.; Radwan, M. M.; Wanas, A. S.; Mehmedic, Z.; Khan, I. I.; Sharaf, M. H. M.; ElSohly, M. A. Determination of 11 Cannabinoids in Biomass and Extracts of Different Varieties of Cannabis Using High-Performance Liquid Chromatography. J. AOAC Int. 2015, 98, 1523–1528. DOI: 10.5740/jaoacint.15-095.
   PubMed Web of Science ®Google Scholar
• Domínguez-Romero, J. C.; García-Reyes, J. F.; Molina-Díaz, A. Screening and Quantitation of Multiclass Drugs of Abuse and Pharmaceuticals in Hair by Fast Liquid Chromatography Electrospray Time-of-Flight Mass Spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879, 2034–2042. DOI: 10.1016/j.jchromb.2011.05.034.
   PubMed Web of Science ®Google Scholar
• Moore, C.; Rana, S.; Coulter, C. Simultaneous Identification of 2-Carboxy-Tetrahydrocannabinol, Tetrahydrocannabinol, Cannabinol and Cannabidiol in Oral Fluid. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 852, 459–464. DOI: 10.1016/j.jchromb.2007.02.016.
   PubMed Web of Science ®Google Scholar
• Nadulski, T.; Pragst, F. Simple and Sensitive Determination of Δ9-Tetrahydrocannabinol, Cannabidiol and Cannabinol in Hair by Combined Silylation, Headspace Solid Phase Microextraction and Gas Chromatography-Mass Spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 846, 78–85. DOI: 10.1016/j.jchromb.2006.08.015.
   PubMed Web of Science ®Google Scholar
• Scheidweiler, K. B.; Desrosiers, N. A.; Huestis, M. A. Simultaneous Quantification of Free and Glucuronidated Cannabinoids in Human Urine by Liquid Chromatography Tandem Mass Spectrometry. Clin. Chim. Acta 2012, 413, 1839–1847. DOI: 10.1016/j.cca.2012.06.034.
   PubMed Web of Science ®Google Scholar
• Nadulski, T.; Sporkert, F.; Schnelle, M.; Stadelmann, A. M.; Roser, P.; Schefter, T.; Pragst, F. Simultaneous and Sensitive Analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in Plasma after Oral Application of Small Doses of THC and Cannabis Extract. J. Anal. Toxicol. 2005, 29, 782–789. DOI: 10.1093/jat/29.8.782.
   PubMed Web of Science ®Google Scholar
• DAI, Q.; TANG, M.; ZHANG, P.; BAO, X.; C, Y. Comparison of the Concentrations of Stiripentol and Its Self-Nanoemulsifying Drug Delivery System in Plasma and Brain of Rats. China Pharm. 2021, 13, 273–277.
   Google Scholar
• Saleh, O. A.; El-Behairy, M. F.; Badawey, A. M.; El-Azzouny, A. A.; Aboul-Enein, H. Y. Analysis of Stiripentol Enantiomers on Several Chiral Stationary Phases: A Comparative Study. Chromatographia 2015, 78, 267–271. DOI: 10.1007/s10337-014-2818-2.
   Web of Science ®Google Scholar
• Takahashi, R.; Imai, K.; Yamamoto, Y.; Takahashi, Y.; Hamano, S.; Yoshida, H. Determination of Stiripentol in Plasma by High-Performance Liquid Chromatography with Fluorescence Detection. Iryo Yakugaku (Japanese J. Pharm. Heal. Care Sci. 2015, 41, 643–650. DOI: 10.5649/jjphcs.41.643.
   Google Scholar
• Darwish, H. W.; Abdelhameed, A. S.; Attia, M. I.; Bakheit, A. H.; Khalil, N. Y.; Al-Majed, A. A. A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form. J. Anal. Methods Chem. 2014, 2014, 638951. DOI: 10.1155/2014/638951.
   PubMed Web of Science ®Google Scholar
• El-Behairy, M. F.; Sundby, E. Synthesis of the Antiepileptic (R)-Stiripentol by a Combination of Lipase Catalyzed Resolution and Alkene Metathesis. Tetrahedron Asymmetry 2013, 24, 285–289. DOI: 10.1016/j.tetasy.2013.02.006.
   Google Scholar
• Gayke, M.; Narode, H.; Eppa, G.; Bhosale, R. S.; Yadav, J. S. Synthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug. ACS Omega 2022, 7, 2486–2503. DOI: 10.1021/acsomega.1c05378.
   PubMed Web of Science ®Google Scholar
• Bhamare, P.; Dubey, R.; Upmanyu, N.; Umadoss, P. A Simple HPLC Method for In-Vitro Dissolution Study of Brivaracetam in Pharmaceutical Dosage Form. Asian J. Pharm. Anal. 2021, 11, 1–8. DOI: 10.5958/2231-5675.2021.00001.6.
   PubMedGoogle Scholar
• Baksam, V.; Saritha, N.; Pocha, V. R.; Chakka, V. B.; Ummadi, R. R.; Kumar, P. Development of an Effective Novel Validated Stability-Indicating HPLC Method for the Resolution of Brivaracetam Stereoisomeric Impurities. Chirality 2020, 32, 1208–1219. DOI: 10.1002/chir.23269.
   PubMed Web of Science ®Google Scholar
• Li, Q.; Zhang, M.; Li, X.; Zhang, Y.; Wang, Z.; Zheng, J. A Novel Lipase from Aspergillus Oryzae WZ007 Catalyzed Synthesis of Brivaracetam Intermediate and Its Enzymatic Characterization. Chirality 2021, 33, 62–71. DOI: 10.1002/chir.23286.
   PubMed Web of Science ®Google Scholar
• Liao, S.; Chen, H.; Wang, G.; Wu, S.; Yang, Z.; Luo, W.; Liu, Z.; Gao, X.; Qin, J.; Li, C-h.; Wang, Z. Identification, Characterization, Synthesis and Strategy for Minimization of Potential Impurities Observed in the Synthesis of Brivaracetam. Tetrahedron 2020, 76, 131273. DOI: 10.1016/j.tet.2020.131273.
   Web of Science ®Google Scholar
• Bhamare, P.; Umadoss, P.; Upmanyu, N.; Dubey, R. Identification, Isolation, Structural Characterisation, Synthesis and: In Silico Toxicity Prediction of the Alkaline Hydrolytic Degradation Product of Brivaracetam by Using LC-PDA, Preparative HPLC, LC/HESI/LTQ, FTIR, and 1H NMR. Anal. Methods 2020, 12, 1868–1881. DOI: 10.1039/C9AY02582K.
   Web of Science ®Google Scholar
• Bourgogne, E.; Culot, B.; Dell’Aiera, S.; Chanteux, H.; Stockis, A.; Nicolas, J.-M. Off-Line Solid Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantitation of Brivaracetam Acid Metabolites: Method Validation and Application to In Vitro Metabolism Assays. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2018, 1086, 138–145. DOI: 10.1016/j.jchromb.2018.04.018.
   PubMed Web of Science ®Google Scholar
• Iqbal, M.; Ezzeldin, E.; Al-Rashood, K. A. UPLC–MS/MS Assay for Identification and Quantification of Brivaracetam in Plasma Sample: Application to Pharmacokinetic Study in Rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2017, 1060, 63–70. DOI: 10.1016/j.jchromb.2017.05.039.
   PubMed Web of Science ®Google Scholar
• Stockis, A.; Sargentini-Maier, M. L.; Brodie, M. J. Pharmacokinetic Interaction of Brivaracetam on Carbamazepine in Adult Patients With Epilepsy, With and Without Valproate Co-Administration. Epilepsy Res. 2016, 128, 163–168. DOI: 10.1016/j.eplepsyres.2016.11.001.
   PubMed Web of Science ®Google Scholar
• Stockis, A.; Rolan, P. Effect of Brivaracetam (400 Mg/Day) on the Pharmacokinetics and Pharmacodynamics of a Combination Oral Contraceptive in Healthy Women. J. Clin. Pharmacol. 2013, 53, 1313–1321. DOI: 10.1002/jcph.187.
   PubMed Web of Science ®Google Scholar
• Raveendra Babu, G.; Sowjanya, M.; Rama Ayyappa, M.; Ravi Kumar, A.; Anusha, C.; Priyanka, A.; Eswari Bhavani, T.; Krishna Sindu, G.; Raja Shekar, K.; Ramesh, D. A Novel Stability-Indicating RP-UPLC Method for the Determination of Cenobamate in Bulk and Pharmaceutical Dosage Forms. Res. J. Pharm. Technol. 2021, 14, 1221–1225. DOI: 10.5958/0974-360X.2021.00217.1.
   Google Scholar
• Vernillet, L.; Greene, S. A.; Kim, H. W.; Melnick, S. M.; Glenn, K. Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects. Eur. J. Drug Metab. Pharmacokinet. 2020, 45, 513–522. DOI: 10.1007/s13318-020-00615-7.
   PubMed Web of Science ®Google Scholar
• Oh, J. H.; Jeong, J. W.; Ji, Y. G.; Shin, Y. M.; Lee, K. R.; Hyung Cho, K.; Koo, T. S. Development of a Liquid Chromatography-Tandem Mass Spectrometry Method for Assaying Cenobamate in Rat Plasma. J. Liq. Chromatogr. Relat. Technol. 2018, 41, 992–997. DOI: 10.1080/10826076.2018.1547743.
   Web of Science ®Google Scholar
• Bibi, D.; Shusterman, B.; Nocentini, A.; Supuran, C. T.; Bialer, M. Stereoselective Pharmacokinetic and Pharmacodynamic Analysis of a CNS-Active Sulphamoylphenyl Carbamate Derivative. J. Enzyme Inhib. Med. Chem. 2019, 34, 1078–1082. DOI: 10.1080/14756366.2019.1612887.
   PubMed Web of Science ®Google Scholar
• Jin, R.; Li, L.; Guo, L.; Li, W.; Shen, Q. A Graphene Tip Coupled with Liquid Chromatography Tandem Mass Spectrometry for the Determination of Four Synthetic Adulterants in Slimming Supplements. Food Chem. 2017, 224, 329–334. DOI: 10.1016/j.foodchem.2016.12.091.
   PubMed Web of Science ®Google Scholar
• Shi, Y.; Sun, C.; Gao, B.; Sun, A. Development of a Liquid Chromatography Tandem Mass Spectrometry Method for Simultaneous Determination of Eight Adulterants in Slimming Functional Foods. J. Chromatogr. A 2011, 1218, 7655–7662. DOI: 10.1016/j.chroma.2011.08.038.
   PubMed Web of Science ®Google Scholar
• WANG, L. I. N. G.; FENG, F. A. N. G.; QUAN WANG, X. U. E.; Z, L. Influences of Urinary PH on the Pharmacokinetics of Three Amphetamine-Type Stimulants Using a New High-Performance Liquid Chromatographic Method. J. Pharm. Sci. 2009, 98, 728–38738. DOI: 10.1002/jps.21438.
   PubMed Web of Science ®Google Scholar
• Kaddoumi, A.; Wada, M.; Nakashima, M. N.; Nakashima, K. Hair Analysis for Fenfluramine and Norfenfluramine as Biomarkers for N-Nitrosofenfluramine Ingestion. Forensic Sci. Int. 2004, 146, 39–46. DOI: 10.1016/j.forsciint.2004.03.018.
   PubMed Web of Science ®Google Scholar
• Kaddoumi, A.; Nakashima, M. N.; Maki, T.; Matsumura, Y.; Nakamura, J.; Nakashima, K. Liquid Chromatography Studies on the Pharmacokinetics of Phentermine and Fenfluramine in Brain and Blood Microdialysates After Intraperitoneal Administration to Rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 791, 291–303. DOI: 10.1016/S1570-0232(03)00231-9.
   PubMed Web of Science ®Google Scholar
• Kaddoumi, A.; Nakashima, M. N.; Nakashima, K. Fluorometric Determination of DL-Fenfluramine, DL-Norfenfluramine and Phentermine in Plasma by Achiral and Chiral High-Performance Liquid Chromatography. J. Chromatogr. B Biomed. Sci. Appl. 2001, 763, 79–90. DOI: 10.1016/S0378-4347(01)00368-1.
   PubMed Web of Science ®Google Scholar
• Namera, A.; Yashiki, M.; Liu, J.; Okajima, K.; Hara, K.; Imamura, T.; Kojima, T. Simple and Simultaneous Analysis of Fenfluramine, Amphetamine and Methamphetamine in Whole Blood by Gas Chromatography-Mass Spectrometry after Headspace-Solid Phase Microextraction and Derivatization. Forensic Sci. Int. 2000, 109, 215–223. DOI: 10.1016/S0379-0738(00)00145-6.
   PubMed Web of Science ®Google Scholar
• Zeng, S.; Mao, H. Q. Stereoselective Determination of Fenfluramine Enantiomers in Rat Liver Microsomal Incubates. J. Chromatogr. B Biomed. Sci. Appl. 1999, 727, 107–112. DOI: 10.1016/S0378-4347(99)00044-4.
   PubMedGoogle Scholar
• Caccia, S.; Jori, A. Gas-Liquid Ckromatographic Determination of the Optical Isomers of Fen- Fluramine and Norfenfluramine in Biological Samples. J. Chromatogr. 1977, 144, 127–131. DOI: 10.1016/0021-9673(77)80016-2.
   PubMed Web of Science ®Google Scholar
• Clausing, P.; Rushing, L. G.; Newport, G. D.; Bowyer, J. F. Determination of D-Fenfluramine, D-Norfenfluramine and Fluoxetine in Plasma, Brain Tissue and Brain Microdialysate Using High Performance Liquid Chromatography After Precolumn Derivatization with Dansyl Chloride. J. Chromatogr. B Biomed. Appl. 1997, 692, 419–426. DOI: 10.1016/S0378-4347(96)00528-2.
   PubMed Web of Science ®Google Scholar
• Zeng, J. N.; Dou, L.; Duda, M.; Stuting, H. H. New Chiral High-Performance Liquid Chromatographic Methodology Used for the Pharmacokinetic Evaluation of Dexfenfluramine. J. Chromatogr. B Biomed. Sci. Appl. 1994, 654, 231–248. DOI: 10.1016/0378-4347(94)00004-2.
   Web of Science ®Google Scholar
• Elizabeth, T. Q. Improved Gas-Liquid Chromatographic Method for Measuring Fenfluramine and Norfenfluramine in Heparinised Plasma. J. Chromatogr. B Biomed. Sci. Appl. 1983, 278, 434–438.
   Google Scholar
• Belvedere, G.; Tognoni, G.; Morselli, P. L. A New Sensitive Gas-Chromatographic Method for the Determination of Fenfluramine in Biological Specimens. Eur. J. Clin. Pharmacol. 1972, 5, 62–64. DOI: 10.1007/BF00560898.
   Web of Science ®Google Scholar
• Campbell, D. B. Gas Chromatographic Measurement of Levels of Fenfluramine and Norfenfluramine in Human Plasma Red Cells and Urine following Therapeutic Doses. J. Chromatogr. A 1970, 49, 442–447. DOI: 10.1016/S0021-9673(00)93657-4.
   PubMed Web of Science ®Google Scholar
• Langer, C.; Süss, R. HPLC-DAD-CAD-Based Approach for the Simultaneous Analysis of Hydrophobic Drugs and Lipid Compounds in Liposomes and for Cyclodextrin/Drug Inclusion Complexes. J. Pharm. Biomed. Anal. 2021, 201, 114120. DOI: 10.1016/j.jpba.2021.114120.
   PubMed Web of Science ®Google Scholar
• Dinéia Perez, J.; Sanches Aragão, D.; Aparecida Ronchi, F.; Febba, A. C.; Rosso, C. F.; Tedesco-Silva Junior, H.; Medina de Abreu Pestana, J. O.; Casarini, D. E. Simultaneous Determination of Everolimus, Sirolimus, Tacrolimus, and Cyclosporine-A by Mass Spectrometry. Transplant Proc. 2020, 52, 1402–1408. DOI: 10.1016/j.transproceed.2020.01.077.
   PubMed Web of Science ®Google Scholar
• Sottani, C.; Grignani, E.; Mazzucchelli, S.; Bonizzi, A.; Corsi, F.; Negri, S.; Prati, F.; Calleri, E.; Cottica, D. Development and Validation of a Simple and Versatile Method for the Quantification of Everolimus Loaded in H-Ferritin Nanocages Using UHPLC-MS/MS. J. Pharm. Biomed. Anal. 2020, 191, 113644. DOI: 10.1016/j.jpba.2020.113644.
   PubMed Web of Science ®Google Scholar
• Taibon, J.; van Rooij, M.; Schmid, R.; Singh, N.; Albrecht, E.; Anne Wright, J.; Geletneky, C.; Schuster, C.; Mörlein, S.; Vogeser, M.; et al. An Isotope Dilution LC-MS/MS Based Candidate Reference Method for the Quantification of Cyclosporine A, Tacrolimus, Sirolimus and Everolimus in Human Whole Blood. Clin. Biochem. 2020, 82, 73–84. DOI: 10.1016/j.clinbiochem.2019.11.006.
   PubMed Web of Science ®Google Scholar
• Krnáč, D.; Reiffová, K.; Rolinski, B. A New HPLC-MS/MS Method for Simultaneous Determination of Cyclosporine A, Tacrolimus, Sirolimus and Everolimus for Routine Therapeutic Drug Monitoring. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2019, 1128, 121772. DOI: 10.1016/j.jchromb.2019.121772.
   PubMed Web of Science ®Google Scholar
• Knapen, L. M.; de Beer, Y.; Brüggemann, R. J. M.; Stolk, L. M.; de Vries, F.; Tjan-Heijnen, V. C. P.; Erp, N. P. V.; Croes, S. Development and Validation of an Analytical Method Using UPLC–MS/MS to Quantify Everolimus in Dried Blood Spots in the Oncology Setting. J. Pharm. Biomed. Anal. 2018, 149, 106–113. DOI: 10.1016/j.jpba.2017.10.039.
   PubMed Web of Science ®Google Scholar
• Giovagnoli, S.; Cassano, T.; Pace, L.; Magini, A.; Polchi, A.; Tancini, B.; Perluigi, M.; De Marco, F.; Emiliani, C.; Dolcetta, D. Evaluation of a LC-MS Method for Everolimus Preclinical Determination in Brain by Using [13C2D4]RAD001 Internal Standard. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2015, 985, 155–163. DOI: 10.1016/j.jchromb.2015.01.035.
   PubMed Web of Science ®Google Scholar
• Kamberi, M.; Tran, T. N. UV-Visible Spectroscopy as an Alternative to Liquid Chromatography for Determination of Everolimus in Surfactant-Containing Dissolution Media: A Useful Approach Based on Solid-Phase Extraction. J. Pharm. Biomed. Anal. 2012, 70, 94–100. DOI: 10.1016/j.jpba.2012.05.038.
   PubMed Web of Science ®Google Scholar
• Mueller, D. M.; Rentsch, K. M. Sensitive Quantification of Sirolimus and Everolimus by LC-MS/MS with Online Sample Cleanup. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2010, 878, 1007–1012. DOI: 10.1016/j.jchromb.2010.02.029.
   PubMed Web of Science ®Google Scholar
• Khoschsorur, G. A.; Fruehwirth, F.; Zelzer, S.; Stettin, M.; Halwachs-Baumann, G. Comparison of Fluorescent Polarization Immunoassay (FPIA) Versus HPLC to Measure Everolimus Blood Concentrations in Clinical Transplantation. Clin. Chim. Acta 2007, 380, 217–221. DOI: 10.1016/j.cca.2007.01.017.
   PubMed Web of Science ®Google Scholar
• Salm, P.; Warnholtz, C.; Boyd, J.; Arabshahi, L.; Marbach, P.; Taylor, P. J. Evaluation of a Fluorescent Polarization Immunoassay for Whole Blood Everolimus Determination Using Samples from Renal Transplant Recipients. Clin. Biochem. 2006, 39, 732–738. DOI: 10.1016/j.clinbiochem.2006.03.019.
   PubMed Web of Science ®Google Scholar
• Baldelli, S.; Zenoni, S.; Merlini, S.; Perico, N.; Cattaneo, D. Simultaneous Determination of Everolimus and Cyclosporine Concentrations by HPLC with Ultraviolet Detection. Clin. Chim. Acta 2006, 364, 354–358. DOI: 10.1016/j.cca.2005.07.019.
   PubMed Web of Science ®Google Scholar